ELVNEnliven Therapeutics, Inc.

ELVN Stock Price, Valuation & Chart | Enliven Therapeutics, Inc.

Compare

$57.860-0.03 (-0.05%)

At close · 01 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology ELVN intrinsic value ELVN calculated fair value vs price

Overview Financials Dividends Ratios

ELVN Historical price chart

ELVN Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization4.13B

PE Ratio-34.65

EPS-1.67

Trading Volume1.04M

Today's High/Low58.34/57.23

Dividend Yield0.00

52 Week High/Low62.32/14.79

Shares Outstanding71.44M

ELVN Financial Statement

ELVN Analyst ratings

ELVN Analysis & performance metrics

ELVN Company profile

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.…

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been…

ELVN Management team

Name

Position

Benjamin HohlCFO

Chief Financial Officer & Head of Corporate Development

Anish Patel Pharm.D.COO

Co-Founder & Chief Operating Officer

Helen Louise Collins M.D.

Chief Medical Officer

Samuel S. Kintz M.B.A.CEO

Co-Founder, Chief Executive Officer, Secretary & Director

Joseph P. Lyssikatos Ph.D.

Co-Founder & Chief Scientific Officer

Galya D. Blachman Esq., Ph.D.

Chief Legal Officer & Head of Business Development

Name

Position

Benjamin HohlCFO

Chief Financial Officer & Head of Corporate Development

Anish Patel Pharm.D.COO

Co-Founder & Chief Operating Officer

Helen Louise Collins M.D.

Chief Medical Officer

Samuel S. Kintz M.B.A.CEO

Co-Founder, Chief Executive Officer, Secretary & Director

Joseph P. Lyssikatos Ph.D.

Co-Founder & Chief Scientific Officer

Galya D. Blachman Esq., Ph.D.

Chief Legal Officer & Head of Business Development

Management Team

Benjamin HohlCFO

Chief Financial Officer & Head of Corporate Development

Anish Patel Pharm.D.COO

Co-Founder & Chief Operating Officer

Helen Louise Collins M.D.

Chief Medical Officer

Samuel S. Kintz M.B.A.CEO

Co-Founder, Chief Executive Officer, Secretary & Director

Joseph P. Lyssikatos Ph.D.

Co-Founder & Chief Scientific Officer

Galya D. Blachman Esq., Ph.D.

Chief Legal Officer & Head of Business Development

Management

Benjamin HohlCFO

Chief Financial Officer & Head of Corporate Development

Anish Patel Pharm.D.COO

Co-Founder & Chief Operating Officer

Helen Louise Collins M.D.

Chief Medical Officer

Samuel S. Kintz M.B.A.CEO

Co-Founder, Chief Executive Officer, Secretary & Director

Joseph P. Lyssikatos Ph.D.

Co-Founder & Chief Scientific Officer

Galya D. Blachman Esq., Ph.D.

Chief Legal Officer & Head of Business Development

Total 6 executives

ELVN Frequently asked questions

What is Enliven Therapeutics, Inc. (ELVN) Stock Price?

Current stock price of Enliven Therapeutics, Inc. (ELVN) stock is $57.860. The stock price is -0.05% lower in the session. The intraday range can be seen from this page. Volume of Enliven Therapeutics, Inc. (ELVN) stock is 1.04M.

Last updated at 01 Sept 2026, 08:00 pm.

Why is the Enliven Therapeutics, Inc. (ELVN) stock price going up or down today?

The stock price of Enliven Therapeutics, Inc. (ELVN) can change with earnings, company news, and overall market sentiment. Enliven Therapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Enliven Therapeutics, Inc. stock expensive at its current price?

Whether Enliven Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for ELVN on this page is -34.65. EPS on this page is -1.67. Compare those figures with peers and growth expectations before deciding if the current Enliven Therapeutics, Inc. price is justified.

How has the stock price of Enliven Therapeutics, Inc. (ELVN) performed historically?

Historical performance for Enliven Therapeutics, Inc. (ELVN) is shown on the price chart on this page. Review multi-period moves alongside volume to see how ELVN reacted to past earnings and market events.

Should I buy Enliven Therapeutics, Inc. (ELVN) stock, at this price?

Buying Enliven Therapeutics, Inc. (ELVN) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.